Neurobo Pharmaceuticals Stock Performance
NRBO Stock | USD 3.10 0.08 2.65% |
On a scale of 0 to 100, Neurobo Pharmaceuticals holds a performance score of 3. The company secures a Beta (Market Risk) of 2.73, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurobo Pharmaceuticals will likely underperform. Please check Neurobo Pharmaceuticals' downside variance, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Neurobo Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Neurobo Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental drivers, Neurobo Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.48 | Five Day Return (11.32) | Year To Date Return (24.70) | Ten Year Return (99.99) | All Time Return (99.99) |
Last Split Factor 1:8 | Dividend Date 2019-12-31 | Last Split Date 2023-12-21 |
1 | NeuroBo to begin Phase 1 testing of potential Wegovy rival | 02/01/2024 |
2 | Does Neurobo Pharmaceuticals Inc Have What it Takes to be in Your Portfolio Tuesday - InvestorsObserver | 02/06/2024 |
3 | NeuroBo stock jumps 14 percent on weight-loss drug update | 02/29/2024 |
4 | Acquisition by Marshall Woodworth of 33496 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 | 03/01/2024 |
5 | NeuroBo Pharmaceuticals appoints Marshall Woodworth as CFO | 03/04/2024 |
6 | Acquisition by Strickland D Gordon of 20000 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 | 03/05/2024 |
7 | Will Neurobo Pharmaceuticals Inc Stay at the Top of the Healthcare Sector - InvestorsObserver | 03/06/2024 |
8 | NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH | 03/13/2024 |
9 | Acquisition by Kim Hyung Heon of 20000 shares of Neurobo Pharmaceuticals subject to Rule 16b-3 | 03/15/2024 |
10 | Acquisition by Jeong Tae Heum of 60000 shares of Neurobo Pharmaceuticals at 8. subject to Rule 16b-3 | 03/25/2024 |
11 | NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update | 03/28/2024 |
12 | NeuroBo Pharmaceuticals Trading Down 3.2 percent - Defense World | 04/02/2024 |
13 | NRBO First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity | 04/23/2024 |
Begin Period Cash Flow | 33.4 M |
Neurobo |
Neurobo Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 307.00 in Neurobo Pharmaceuticals on January 26, 2024 and sell it today you would earn a total of 3.00 from holding Neurobo Pharmaceuticals or generate 0.98% return on investment over 90 days. Neurobo Pharmaceuticals is currently generating 0.4237% in daily expected returns and assumes 10.2282% risk (volatility on return distribution) over the 90 days horizon. In different words, 90% of stocks are less volatile than Neurobo, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Neurobo Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurobo Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurobo Pharmaceuticals, and traders can use it to determine the average amount a Neurobo Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0414
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | NRBO | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
10.23 actual daily | 90 90% of assets are less volatile |
Expected Return
0.42 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Neurobo Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurobo Pharmaceuticals by adding it to a well-diversified portfolio.
Neurobo Pharmaceuticals Fundamentals Growth
Neurobo Stock prices reflect investors' perceptions of the future prospects and financial health of Neurobo Pharmaceuticals, and Neurobo Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurobo Stock performance.
Return On Equity | -0.65 | ||||
Return On Asset | -0.35 | ||||
Current Valuation | (7.42 M) | ||||
Shares Outstanding | 4.91 M | ||||
Price To Earning | (1.44) X | ||||
Price To Book | 1.06 X | ||||
Revenue | 7 K | ||||
EBITDA | (15.88 M) | ||||
Net Income | (12.47 M) | ||||
Cash And Equivalents | 8.85 M | ||||
Cash Per Share | 9.96 X | ||||
Total Debt | 203 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 8.07 X | ||||
Book Value Per Share | 3.40 X | ||||
Cash Flow From Operations | (10.8 M) | ||||
Earnings Per Share | (2.46) X | ||||
Market Capitalization | 14.82 M | ||||
Total Asset | 22.78 M | ||||
Retained Earnings | (108.27 M) | ||||
Working Capital | 16.55 M | ||||
Current Asset | 21.62 M | ||||
Current Liabilities | 11.75 M | ||||
About Neurobo Pharmaceuticals Performance
To evaluate Neurobo Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Neurobo Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Neurobo Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Neurobo Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Neurobo's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 0.00 | 0.00 | |
Return On Tangible Assets | (0.55) | (0.57) | |
Return On Capital Employed | (0.94) | (0.99) | |
Return On Assets | (0.55) | (0.57) | |
Return On Equity | (0.75) | (0.78) |
Things to note about Neurobo Pharmaceuticals performance evaluation
Checking the ongoing alerts about Neurobo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurobo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Neurobo Pharmaceuticals had very high historical volatility over the last 90 days | |
The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Neurobo Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Roughly 62.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from finance.yahoo.com: NRBO First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity |
- Analyzing Neurobo Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurobo Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Neurobo Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurobo Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurobo Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurobo Pharmaceuticals' stock. These opinions can provide insight into Neurobo Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Neurobo Stock analysis
When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.35) | Return On Equity (0.65) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.